MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Counterfeit Response
20 questions · exam conditions
0:00
Counterfeit ResponseQuestion 1 of 20

After quarantining a suspect product, a pharmacy investigates with its trading partners and cannot verify the product's legitimacy. DSCSA classifies the product as illegitimate. Within what timeframe must the pharmacy notify the FDA?

Within 72 hours of the initial quarantine.
Within 24 hours of making the determination that the product is illegitimate.
Within 30 days of the initial suspicion.
Notification to the FDA is optional; only notification to trading partners is required.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Counterfeit Response

Practice Counterfeit Response in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Counterfeit Response, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

After quarantining a suspect product, a pharmacy investigates with its trading partners and cannot verify the product's legitimacy. DSCSA classifies the product as illegitimate. Within what timeframe must the pharmacy notify the FDA?

  1. Within 72 hours of the initial quarantine.
  2. Within 24 hours of making the determination that the product is illegitimate. (correct answer)
  3. Within 30 days of the initial suspicion.
  4. Notification to the FDA is optional; only notification to trading partners is required.
Explanation: Under DSCSA, once a pharmacy determines that a product is illegitimate -- meaning it has been confirmed as counterfeit, diverted, stolen, or intentionally adulterated -- the pharmacy must notify the FDA within 24 hours of making that determination. B correctly states this timeframe. A is incorrect because the 24-hour clock runs from the illegitimacy determination, not from the initial quarantine. C is incorrect because 30 days far exceeds the 24-hour requirement. D is incorrect because FDA notification is mandatory, not optional, upon confirmation of illegitimacy.

Question 2

A community pharmacist discovers that a patient has been self-administering medications purchased from an online pharmacy that appears to be operating illegally. The patient shows the pharmacist the packaging, which lacks FDA-required labeling elements. Which of the following best describes the pharmacist's appropriate response?

  1. The pharmacist should dispense the patient's current prescription and say nothing about the online source.
  2. The pharmacist should counsel the patient on risks of purchasing from unverified online pharmacies. (correct answer)
  3. The pharmacist must immediately confiscate the patient's medications.
  4. The pharmacist must report the patient to the DEA.
Explanation: Patient counseling about the risks of illegal online pharmacies is appropriate and within the pharmacist's professional role. The pharmacist should inform the patient about risks of counterfeit or substandard products and encourage use of verified pharmacies. B correctly identifies this patient-protective response. A is incorrect because a pharmacist who is aware of a patient safety risk has a professional obligation to counsel. C is incorrect because pharmacists do not have authority to confiscate patients' medications. D is incorrect because a patient purchasing medications for personal use does not trigger DEA reporting.

Question 3

A wholesale distributor notifies a pharmacy that a lot of insulin it recently received may have been diverted from the legitimate supply chain. The pharmacy has not yet dispensed any units. What must the pharmacy do first?

  1. Quarantine all units of the identified lot immediately to prevent dispensing while the investigation proceeds. (correct answer)
  2. Dispense remaining units quickly before the recall can be formalized.
  3. Return the units to the distributor without conducting any pharmacy-level investigation.
  4. Notify patients who will be affected by the potential shortage.
Explanation: The immediate first step upon receiving a suspect product notification -- even before any units have been dispensed -- is quarantine. A correctly identifies this required action. B is incorrect because dispensing suspect product after notification would be a serious DSCSA violation and patient safety breach. C is incorrect because quarantine and investigation must precede any product return under DSCSA. D is incorrect because patient shortage notification is not the required first step when suspect product is identified; quarantine takes priority.

Question 4

A pharmacy's DSCSA verification system identifies a product's 2D barcode as not matching the manufacturer's database. The product is an oncology injectable with a current expiration date. Which of the following best describes the required action?

  1. The pharmacy may dispense the product because the expiration date is current and the product appears clinically appropriate.
  2. The pharmacy should dispense one unit and observe for patient reaction before deciding whether to quarantine the remaining units.
  3. The pharmacy should contact the manufacturer for a manual override of the verification failure.
  4. The pharmacy must not dispense any units of this product; a verification failure triggers suspect product status requiring quarantine and investigation regardless of expiration date or clinical appearance. (correct answer)
Explanation: A 2D barcode verification failure triggers suspect product status under DSCSA regardless of expiration date or visual appearance. The product must be quarantined immediately and the investigation initiated. D correctly identifies this required response. A is incorrect because current expiration date does not override a DSCSA verification failure. B is incorrect because dispensing to observe patient reaction is a patient safety violation when a product has failed verification. C is incorrect because a manufacturer manual override of a verification failure is not a recognized DSCSA process.

Question 5

A pharmacy staff member visually inspects a prescription product at receiving and notices the anti-counterfeiting hologram on the packaging appears to be a photocopy rather than an authentic hologram. Which of the following most accurately describes the appropriate response?

  1. Accept the product because holograms are an older anti-counterfeiting technology and variations are expected.
  2. Accept the product but log the observation for future reference.
  3. Quarantine the product and start a suspect product investigation per DSCSA guidelines. (correct answer)
  4. Return the product to the driver immediately without documenting the suspected counterfeiting.
Explanation: A photocopied hologram is a significant anti-counterfeiting red flag that must trigger quarantine and DSCSA investigation. C correctly identifies this required response. A is incorrect because hologram variations do not explain a clearly photocopied authenticity feature. B is incorrect because logging without quarantine allows a potentially counterfeit product to be dispensed during the logging period. D is incorrect because returning the product to the delivery driver without documentation eliminates the chain-of-custody record needed for DSCSA investigation.

Question 6

A pharmacy receives a notice from the FDA that a specific drug product it dispenses has been identified as a target for counterfeiting based on market analysis. No specific lot has been identified as counterfeit. Which of the following best describes the pharmacy's appropriate response?

  1. Continue current practice without changes because no specific lot has been identified as counterfeit.
  2. Immediately discontinue dispensing the product entirely.
  3. Enhance verification procedures and train staff on identifying counterfeit indicators for the specific drug. (correct answer)
  4. Report all current inventory to the FDA for testing before dispensing any further units.
Explanation: An FDA notice that a product is a counterfeiting target warrants enhanced vigilance, including more thorough verification procedures, staff training on counterfeit indicators, increased scrutiny of transaction information and serialized product identifier verification under DSCSA's enhanced tracing requirements, and active monitoring for suspicious characteristics. C correctly identifies this proportionate, proactive response. A is incorrect because a known counterfeiting target warrants enhanced scrutiny even without identification of a specific affected lot. B is incorrect because complete discontinuation based on a general counterfeiting risk notice is disproportionate and may deny patients needed medications. D is incorrect because submitting all current inventory for FDA testing before dispensing is not a standard process available to pharmacies.

Question 7

A pharmacist receives a prescription for an oncology medication and notices the tablets have an unusual color and the packaging seal appears to have been tampered with. The batch number does not appear in the manufacturer's verification system. Which of the following is the most appropriate immediate action?

  1. Dispense the medication and report the concern to the manufacturer after dispensing.
  2. Dispense the medication because batch number look-up failures are common system glitches.
  3. Quarantine the product and contact the manufacturer for verification before taking further action. (correct answer)
  4. Return the product to the distributor without documentation.
Explanation: Multiple simultaneous indicators of a potentially counterfeit product -- color inconsistency, tampered packaging seal, and failed batch verification -- require immediate quarantine and investigation. A is incorrect because dispensing a potentially counterfeit oncology product before investigation poses serious patient safety risk. B is incorrect because multiple concurrent red flags cannot be dismissed as system errors. D is incorrect because returning the product without documentation eliminates chain-of-custody records required by DSCSA.

Question 8

A pharmacy receives notification from a trading partner that a product in the pharmacy's current inventory may be illegitimate. The pharmacy has dispensed 15 units to patients over the past week. Which of the following best describes the pharmacy's full set of obligations?

  1. Quarantine remaining stock only; patients who received product before notification are not the pharmacy's responsibility.
  2. Return all remaining stock to the distributor and consider the matter resolved.
  3. Destroy remaining stock immediately to prevent further patient harm.
  4. Quarantine remaining stock, investigate with trading partners, and notify FDA within 24 hours if confirmed. (correct answer)
Explanation: DSCSA obligations require quarantine, investigation, FDA notification upon confirmation of illegitimacy, and trading partner notification. When patients have already received potentially illegitimate product, the pharmacy must also assess patient notification and clinical follow-up needs. A is incorrect because the pharmacy's responsibility extends to patients who have already received the product. B is incorrect because returning the product before completing the investigation does not satisfy DSCSA investigation obligations. C is incorrect because immediate destruction is not authorized and would eliminate evidence needed for the investigation.

Question 9

A pharmacy discovers that a controlled substance it received is confirmed counterfeit. Under DSCSA, the pharmacy must notify the FDA. What additional reporting obligation may apply under DEA regulations?

  1. No DEA reporting is required for a confirmed counterfeit controlled substance because DSCSA reporting to FDA satisfies all federal obligations.
  2. The pharmacy must file DEA Form 106 if the counterfeit discovery suggests significant loss or diversion of controlled substances. (correct answer)
  3. The pharmacy must file DEA Form 222 to document the discovery of counterfeit controlled substances.
  4. The pharmacy must submit a written statement to the DEA regional office within 30 days.
Explanation: If authentic controlled substances were replaced with counterfeits -- a form of diversion -- DEA Form 106 would be required to report the theft or significant loss of the authentic product. B correctly identifies this parallel DEA reporting obligation. A is incorrect because DSCSA FDA reporting and DEA loss reporting address different aspects of the same event and both may apply. C is incorrect because DEA Form 222 is used for ordering Schedule I and II controlled substances, not for reporting counterfeiting. D is incorrect because a 30-day written statement is not the required mechanism; DEA Form 106 is.

Question 10

A pharmacy's DSCSA suspect product investigation is still ongoing at the 30-day mark. The product remains quarantined. No definitive determination of legitimacy or illegitimacy has been made. Which of the following best describes the appropriate course of action?

  1. After 30 days the product may be released from quarantine and dispensed because the investigation period has concluded.
  2. The pharmacy may dispense the product if no further red flags have emerged during the 30-day investigation period.
  3. Continue quarantine and notify the FDA if the product is deemed illegitimate; DSCSA requires determination before release. (correct answer)
  4. The pharmacy should request a DSCSA investigation extension from the state board of pharmacy to allow additional time before making a determination.
Explanation: Quarantine under DSCSA continues until a definitive determination of legitimacy or illegitimacy is reached, not until a set time period has elapsed. An inconclusive investigation after reasonable efforts results in the product being treated as illegitimate. C correctly identifies this standard. A is incorrect because passage of time does not authorize release from quarantine under DSCSA. B is incorrect because the absence of additional red flags during the investigation period is not the standard for release; verification of legitimacy is required. D is incorrect because DSCSA investigation extensions are not granted by state boards of pharmacy.

Question 11

A pharmacist is approached by a patient who believes the medication she received last month from a different pharmacy was counterfeit based on its appearance and lack of expected effect. Which of the following best describes the pharmacist's appropriate response?

  1. Advise the patient to post a complaint on social media about the dispensing pharmacy.
  2. Tell the patient that pharmacies never dispense counterfeit medications.
  3. Tell the patient to contact her health insurer about the suspected product.
  4. Advise the patient to report the suspected counterfeit medication to the dispensing pharmacy and FDA. (correct answer)
Explanation: When a patient reports suspected counterfeit medication, the pharmacist should direct her to report it through appropriate channels -- the dispensing pharmacy, her prescriber, and FDA MedWatch -- and document the conversation. D correctly identifies these patient-protective actions. A is incorrect because social media complaints are not the appropriate regulatory reporting pathway. B is incorrect because counterfeit medications do occasionally enter the supply chain and dismissing the concern is professionally inappropriate. C is incorrect because insurance notification is not the relevant reporting pathway for suspected counterfeiting.

Question 12

A pharmacy is investigating a suspect product and must decide whether to request enhanced due diligence documentation from its trading partner. Which of the following DSCSA documents would provide the most direct evidence of the product's supply chain legitimacy?

  1. The trading partner's state pharmacy license.
  2. The manufacturer's press release announcing the product's approval.
  3. The trading partner's internal quality control checklist.
  4. Transaction information and statement from the interoperable tracing system. (correct answer)
Explanation: Under DSCSA's enhanced drug tracing requirements, the most direct evidence of a product's supply chain legitimacy is verification of the serialized product identifier through the interoperable electronic tracing system, supported by the transaction information and transaction statement accompanying the most recent transfer. These elements together allow the pharmacy to confirm that the specific product lot was handled through the authorized domestic supply chain. Note that transaction history as a standalone chain-of-custody document is no longer part of the current DSCSA tracing standard. D correctly identifies the current evidentiary framework. A is incorrect because trading partner licensure confirms authorization to distribute but does not verify this specific product lot's supply chain integrity. B is incorrect because a manufacturer approval announcement does not document this lot's chain of custody. C is incorrect because an internal quality checklist does not document the external supply chain history required by DSCSA.

Question 13

A pharmacy purchases medications from a secondary wholesaler offering significantly below-market prices. The distributor is licensed but the transaction information provided is incomplete. Which of the following best analyzes the DSCSA compliance concern?

  1. There is no compliance concern because the distributor is licensed.
  2. There is no compliance concern as long as the medications are within their expiration dates.
  3. Incomplete transaction information raises suspicion of counterfeit products; the pharmacy must verify legitimacy before dispensing. (correct answer)
  4. The pharmacy may dispense but must charge patients the full market price to offset the purchasing risk.
Explanation: Below-market pricing and incomplete supply chain documentation are significant red flags for potentially diverted or counterfeit products under DSCSA's enhanced drug tracing requirements. The pharmacy should treat these products as suspect, request complete transaction information and a transaction statement from the trading partner, and verify the serialized product identifier through the interoperable electronic tracing system before dispensing. C correctly identifies this risk-based analysis. A is incorrect because distributor licensure alone does not guarantee product legitimacy or DSCSA compliance. B is incorrect because an expiration date is not a substitute for supply chain traceability verification. D is incorrect because pricing strategies have no bearing on DSCSA compliance obligations.

Question 14

A pharmacist receives a report from a patient who experienced a serious adverse reaction to what appears to be a subpotent medication. Upon examination, the pharmacist finds the lot number does not appear in the manufacturer's verification database. Which of the following best describes the initial required actions?

  1. Quarantine the lot, report to FDA, investigate as suspect product, notify prescriber. (correct answer)
  2. Dispense remaining units and await FDA guidance before taking further action.
  3. Report the situation to the DEA as a possible controlled substance adulteration.
  4. Tell the patient to contact her health insurance company.
Explanation: Multiple actions are simultaneously triggered: the product must be quarantined as a DSCSA suspect product, the adverse reaction should be reported to FDA MedWatch, a DSCSA investigation must be initiated, and the prescriber should be informed. A correctly identifies this comprehensive multi-action response. B is incorrect because dispensing additional units from a suspect lot while awaiting FDA guidance creates ongoing patient safety risk. C is incorrect because the DEA is not the appropriate authority for adulterated drug reporting absent a controlled substance connection. D is incorrect because insurance notification is not a relevant initial response to a suspect counterfeit drug adverse event.

Question 15

A pharmacy's investigation of a suspect product cannot reach a definitive conclusion because the trading partner is unresponsive and batch records cannot be retrieved. Which of the following best analyzes this situation?

  1. The pharmacy may resume dispensing because the investigation was completed to the best of the pharmacy's ability.
  2. The pharmacy must treat the product as illegitimate and notify the FDA, without dispensing it. (correct answer)
  3. The pharmacy may dispense the product if the prescribing physician provides written confirmation of need.
  4. The pharmacy should contact the state board of pharmacy to request a variance allowing dispensing.
Explanation: If a pharmacy cannot verify a product's legitimacy after a good-faith investigation, the product must be treated as illegitimate. Inability to verify does not equal verification of legitimacy. B correctly identifies the risk-based approach required by DSCSA. A is incorrect because an inconclusive investigation does not authorize resumption of dispensing. C is incorrect because a prescriber's clinical need does not authorize dispensing a potentially counterfeit product. D is incorrect because a state board variance does not address federal DSCSA obligations.

Question 16

A hospital pharmacist discovers that a batch of compounded sterile injectable medications received from a 503B outsourcing facility has unlabeled vials mixed among labeled ones. The 503B facility's records do not account for these unlabeled vials. Which of the following best describes the pharmacist's obligations?

  1. The pharmacist may dispense the labeled vials and discard the unlabeled ones.
  2. Quarantine the entire batch, contact the 503B facility and the FDA, and do not use any vials until the issue is resolved. (correct answer)
  3. The pharmacist should administer the labeled vials first while investigating the unlabeled ones.
  4. The pharmacist should send the unlabeled vials to a laboratory for testing before deciding whether to use any vials from the batch.
Explanation: Unlabeled vials mixed among a labeled batch that are unaccounted for in facility records is a significant quality and safety concern that requires quarantining the entire batch, not just the unlabeled vials. The FDA and the 503B facility must be notified. B correctly identifies this comprehensive response. A is incorrect because the presence of unaccounted unlabeled vials casts doubt on the integrity of the entire batch, not only the unlabeled units. C is incorrect because administering labeled vials while investigating unlabeled ones exposes patients to potential risk from a compromised batch. D is incorrect because laboratory testing of unlabeled vials alone without quarantining the entire batch does not address the safety concern.

Question 17

FDA's Operation Pangea targets illegal online pharmacies. What are pharmacists' professional responsibilities related to this issue?

  1. Pharmacists should educate patients on risks and report suspected illegal online pharmacies to the FDA. (correct answer)
  2. Pharmacists are not responsible for addressing illegal online pharmacies because these are a law enforcement matter.
  3. Pharmacists must refuse to dispense prescriptions to patients who admit to having used online pharmacies.
  4. Pharmacists must report all patients who disclose online pharmacy use to the state board of pharmacy.
Explanation: Pharmacists have a professional responsibility to counsel patients about the risks of illegal online pharmacies, direct them to verified sources, and report suspected illegal activity to the FDA. A correctly identifies these responsibilities. B is incorrect because patient safety counseling and illegal online pharmacy awareness are within the pharmacist's professional scope. C is incorrect because a patient's prior use of an online pharmacy does not create grounds to refuse current legitimate prescription dispensing. D is incorrect because patients who have used online pharmacies are not in violation of any law requiring mandatory reporting.

Question 18

Under DSCSA's enhanced drug tracing requirements, what documentation must accompany each prescription drug product transfer, and what are pharmacies' retention obligations?

  1. Pharmacies must receive a transaction statement only; transaction information is the distributor's responsibility to retain.
  2. Pharmacies must receive and retain transaction information and statements for 6 years for FDA inspection. (correct answer)
  3. Transaction documentation is optional for transfers between licensed entities that have an existing business relationship.
  4. Pharmacies must receive transaction documentation but are only required to retain it for 6 months.
Explanation: Under DSCSA's enhanced drug tracing framework, each transfer of a prescription drug product must be accompanied by transaction information and a transaction statement. Pharmacies must receive these documents, retain them for at least 6 years, and produce them for FDA inspection upon request. The enhanced tracing system also requires that serialized product identifiers be verifiable through the interoperable electronic product tracing system. Note that transaction history as a standalone chain-of-custody document is no longer part of the current DSCSA tracing requirement. A is incorrect because both transaction information and a transaction statement are required at the pharmacy level, not just the statement. C is incorrect because existing business relationships do not create exceptions to DSCSA documentation requirements. D is incorrect because 6 months is far below the 6-year retention requirement.

Question 19

A pharmacy must dispose of a product confirmed to be illegitimate under DSCSA. Which of the following best describes the required disposition process?

  1. The pharmacy may immediately dispose of the product in any manner it chooses once the FDA has been notified.
  2. The pharmacy must return the product to the distributor who provided it.
  3. The pharmacy must immediately destroy the product on site to prevent any risk of diversion.
  4. The pharmacy must quarantine the product, notify the FDA and trading partners, and dispose of it per regulatory requirements. (correct answer)
Explanation: Once a product is confirmed illegitimate under DSCSA, the pharmacy must quarantine it to prevent dispensing, notify the FDA and affected trading partners, and dispose of it in a manner that removes it permanently from the supply chain. DSCSA does not require FDA authorization before each individual disposal act; rather, the pharmacy must follow applicable disposal regulations, which include DEA requirements if the product is a controlled substance. D correctly describes these obligations. A is incorrect because FDA notification alone does not authorize unrestricted disposal; applicable disposal regulations must be followed. B is incorrect because returning a confirmed illegitimate product to a trading partner would re-introduce it into commerce, which DSCSA prohibits. C is incorrect because immediate unilateral on-site destruction without following applicable disposal regulations may itself violate DEA or other requirements.

Question 20

When a pharmacy identifies a suspect product under DSCSA, which of the following is the correct immediate action?

  1. The pharmacy must immediately quarantine the suspect product, segregating it from dispensing stock to prevent it from reaching patients while the investigation proceeds. (correct answer)
  2. The pharmacy must immediately contact the DEA to report the suspected counterfeit product.
  3. The pharmacy should continue dispensing while notifying the manufacturer by mail.
  4. The pharmacy should return the product to the distributor and request a credit before conducting any investigation.
Explanation: The first required action under DSCSA upon identifying a suspect product is to quarantine it -- segregating it from dispensing stock so it cannot be dispensed to patients during the investigation. A correctly identifies this immediate obligation. B is incorrect because DEA is not the primary authority for DSCSA suspect product reporting; the FDA and trading partners are. C is incorrect because continuing to dispense a suspect product is a serious patient safety and regulatory violation. D is incorrect because returning the product before completing the investigation eliminates the ability to perform required DSCSA verification and documentation.